STRATA SKIN SCIENCES INC (SSKN) Stock Fundamental Analysis
USA - NASDAQ:SSKN - US86272A3059 - Common Stock
1.65 USD
-0.06 (-3.51%)
We assign a fundamental rating of 1 out of 10 to SSKN. SSKN was compared to 189 industry peers in the Health Care Equipment & Supplies industry. SSKN has a bad profitability rating. Also its financial health evaluation is rather negative. SSKN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SSKN had negative earnings in the past year.
In the past year SSKN has reported a negative cash flow from operations.
SSKN had negative earnings in each of the past 5 years.
In multiple years SSKN reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of -37.56%, SSKN is not doing good in the industry: 60.85% of the companies in the same industry are doing better.
SSKN has a Return On Equity of -3746.75%. This is amonst the worse of the industry: SSKN underperforms 89.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.56% | ||
| ROE | -3746.75% | ||
| ROIC | N/A |
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 57.89%, SSKN perfoms like the industry average, outperforming 56.61% of the companies in the same industry.
In the last couple of years the Gross Margin of SSKN has declined.
The Profit Margin and Operating Margin are not available for SSKN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.89% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
2. Health
2.1 Basic Checks
SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SSKN has more shares outstanding
The number of shares outstanding for SSKN has been reduced compared to 5 years ago.
Compared to 1 year ago, SSKN has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -10.97, we must say that SSKN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -10.97, SSKN is not doing good in the industry: 79.89% of the companies in the same industry are doing better.
SSKN has a Debt/Equity ratio of 49.58. This is a high value indicating a heavy dependency on external financing.
SSKN has a worse Debt to Equity ratio (49.58) than 90.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 49.58 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.97 |
ROIC/WACCN/A
WACC10.13%
2.3 Liquidity
SSKN has a Current Ratio of 0.98. This is a bad value and indicates that SSKN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of SSKN (0.98) is worse than 88.89% of its industry peers.
A Quick Ratio of 0.75 indicates that SSKN may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.75, SSKN is doing worse than 85.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.75 |
3. Growth
3.1 Past
The earnings per share for SSKN have decreased strongly by -16.87% in the last year.
SSKN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.36%.
Measured over the past years, SSKN shows a small growth in Revenue. The Revenue has been growing by 1.22% on average per year.
EPS 1Y (TTM)-16.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1900%
Revenue 1Y (TTM)0.36%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-9.15%
3.2 Future
SSKN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.30% yearly.
Based on estimates for the next years, SSKN will show a small growth in Revenue. The Revenue will grow by 4.04% on average per year.
EPS Next Y37.76%
EPS Next 2Y28.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-1.34%
Revenue Next 2Y4.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SSKN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SSKN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SSKN's earnings are expected to grow with 28.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.3%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SSKN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:SSKN (11/12/2025, 2:39:36 PM)
1.65
-0.06 (-3.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners29.88%
Inst Owner Change-4.27%
Ins Owners3.09%
Ins Owner Change0%
Market Cap8.70M
Revenue(TTM)32.85M
Net Income(TTM)-11.54M
Analysts85
Price Target8.16 (394.55%)
Short Float %45.92%
Short Ratio0.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-57.4%
Min EPS beat(2)-104.6%
Max EPS beat(2)-10.2%
EPS beat(4)0
Avg EPS beat(4)-101.01%
Min EPS beat(4)-271.14%
Max EPS beat(4)-10.2%
EPS beat(8)2
Avg EPS beat(8)-96.62%
EPS beat(12)4
Avg EPS beat(12)-54.24%
EPS beat(16)7
Avg EPS beat(16)-36.31%
Revenue beat(2)0
Avg Revenue beat(2)-10.27%
Min Revenue beat(2)-12.25%
Max Revenue beat(2)-8.28%
Revenue beat(4)2
Avg Revenue beat(4)-3.72%
Min Revenue beat(4)-12.25%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-5.92%
Revenue beat(12)5
Avg Revenue beat(12)-3.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.73%
PT rev (1m)0%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-70.8%
EPS NY rev (1m)0%
EPS NY rev (3m)-35.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.9%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.26 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 28.23 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.84
EYN/A
EPS(NY)-0.95
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS6.23
BVpS0.06
TBVpS-1.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.56% | ||
| ROE | -3746.75% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.89% | ||
| FCFM | N/A |
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score3
Asset Turnover1.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 49.58 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 14.87% | ||
| Cap/Sales | 2.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.98 | ||
| Quick Ratio | 0.75 | ||
| Altman-Z | -10.97 |
F-Score3
WACC10.13%
ROIC/WACCN/A
Cap/Depr(3y)63.47%
Cap/Depr(5y)69.64%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1900%
EPS Next Y37.76%
EPS Next 2Y28.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.36%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%-9.15%
Revenue Next Year-1.34%
Revenue Next 2Y4.04%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year114.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.81%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%
STRATA SKIN SCIENCES INC / SSKN FAQ
What is the fundamental rating for SSKN stock?
ChartMill assigns a fundamental rating of 1 / 10 to SSKN.
Can you provide the valuation status for STRATA SKIN SCIENCES INC?
ChartMill assigns a valuation rating of 1 / 10 to STRATA SKIN SCIENCES INC (SSKN). This can be considered as Overvalued.
How profitable is STRATA SKIN SCIENCES INC (SSKN) stock?
STRATA SKIN SCIENCES INC (SSKN) has a profitability rating of 1 / 10.